Moomoo AIのまとめ
Reneo Pharmaceuticals, Inc. (Reneo Pharmaceuticals), a clinical-stage pharmaceutical company, has filed an amended annual report (Form 10-K/A) with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The amendment includes information required by Part III of Form 10-K, which was previously omitted from the original filing. The company has stated that the amendment does not modify or update any previously reported financial results nor does it change any financial statements. The filing includes details about the company's directors, executive officers, and corporate governance, as well as executive compensation and equity ownership among certain beneficial owners and management. Reneo Pharmaceuticals' common stock is registered under the symbol RPHM and is traded on The...Show More
Reneo Pharmaceuticals, Inc. (Reneo Pharmaceuticals), a clinical-stage pharmaceutical company, has filed an amended annual report (Form 10-K/A) with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The amendment includes information required by Part III of Form 10-K, which was previously omitted from the original filing. The company has stated that the amendment does not modify or update any previously reported financial results nor does it change any financial statements. The filing includes details about the company's directors, executive officers, and corporate governance, as well as executive compensation and equity ownership among certain beneficial owners and management. Reneo Pharmaceuticals' common stock is registered under the symbol RPHM and is traded on The Nasdaq Stock Market LLC. The company's shares are held by a number of significant investors, including entities affiliated with New Enterprise Associates, Tang Capital Partners, LP, and Abingworth Bioventures 8 LP. The company has also entered into indemnification agreements with its directors and executive officers and maintains a severance benefit plan for its named executive officers. The filing confirms that the majority of the company's board members are independent as defined by Nasdaq Listing Rules. Ernst & Young LLP serves as the company's independent registered public accounting firm.
臨床段階の医薬品会社であるReneo Pharmaceuticals, Inc.（Reneo Pharmaceuticals）は、2023年12月31日に終了した決算年度の修正済み年次報告書（Form 10-K/A）を米国証券取引委員会（SEC）に提出しました。修正には、元の申告書から以前省略されていたForm 10-KのPart IIIで必要な情報が含まれています。同社は、修正が以前に報告された財務結果を修正または更新するものではなく、財務諸表にも変更を加えないことを述べています。申告書には、同社の取締役、重役、コーポレートガバナンスの詳細、また一部の有益所有者や管理職の経営者報酬や株式所有...すべて展開
臨床段階の医薬品会社であるReneo Pharmaceuticals, Inc.（Reneo Pharmaceuticals）は、2023年12月31日に終了した決算年度の修正済み年次報告書（Form 10-K/A）を米国証券取引委員会（SEC）に提出しました。修正には、元の申告書から以前省略されていたForm 10-KのPart IIIで必要な情報が含まれています。同社は、修正が以前に報告された財務結果を修正または更新するものではなく、財務諸表にも変更を加えないことを述べています。申告書には、同社の取締役、重役、コーポレートガバナンスの詳細、また一部の有益所有者や管理職の経営者報酬や株式所有に関する情報が含まれています。Reneo Pharmaceuticalsの普通株式はシンボルRPHMで登録され、The Nasdaq Stock Market LLCで取引されています。同社の株式は、New Enterprise Associates、Tang Capital Partners、LP、Abingworth Bioventures 8 LPなどの重要な投資家によって保有されています。同社はまた、取締役や重役との免責契約を締結し、その指名された重役のための退職給付計画を維持しています。申告書は、同社の取締役会の過半数がナスダックの上場規則で定義される独立したものであることを確認しています。Ernst & Young LLPは同社の独立登録公開会計士として務めています。
役に立った
役に立たない